A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs INCB 50465 (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-203
- Sponsors Incyte Corporation
- 18 Nov 2017 Study protocol has been amended for this trial and multiple fields in the profile are changed.Comparator drug Idelalisib has been removed from the study hence treatment arms changed from 3 to 2.Study title and purpose also changed. Study design changed from randomized to non-randomized. Patient number changed from 180 to 100.
- 18 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
- 18 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.